Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit



Therapeutic HPV vaccine trial +/- anti-CD40 in HPV-driven squamous cell carcinoma. 


HARE-40 is a phase I/II vaccine dose escalation study for HPV16+ Squamous Cell Carcinoma.


Primary objective

To establish a safe and tolerable dose of the HPV vaccine.

Secondary objectives

Looking at clinical effect in advance HPV-driven cancers and to assess if these clinical effects are linked with immune effects in the blood and tissue.

Trial Design

Each patient will progress through an intra-patient dose escalation for a total of 8 vaccinations, comprising of 4 weekly vaccinations and 4 fortnightly vaccinations. During this time, patients will be expected to stay overnight for a period of 24 hours after the vaccination. Patients will then be followed up for a period of 2 years, attending follow-up visits at regular intervals.

Trial Status

Open to recruitment


Initially, the trial will recruit to two Arms:

  • Arm 1A will recruit 15 patients who have been previously treated for HPV16+ Head and Neck SCC. 
  • Arm 1B will recruit 29 patients with advanced HPV16+ SCC of Head and Neck, Penile, Cervical and Anogential.

Trial Team:

Senior Trial Manager:

Karen Martin (023 8120 3507)

Trial Manager:

Anna Smith (023 8120 3833)

Trial Monitor:

Marina Lee (023 8120 3747)

Clinical Data Coordinator:

Kathrin Eichhorst (023 8120 5697)

Contact information


Fax: 0844 774 0621

SAE Reporting:


Fax: +49 (0) 231 700 118 68


Privacy Settings